Hsiao Wei-Ling, Hung Wan-Ting, Yang Chen-Hao, Lai Yeur-Hur, Kuo Shuenn-Wen, Liao Hsien-Chi
School of Nursing, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
J Formos Med Assoc. 2023 Dec;122(12):1247-1254. doi: 10.1016/j.jfma.2023.05.016. Epub 2023 Jun 4.
BACKGROUND/PURPOSE: Patients with esophageal cancer who undergo minimally invasive esophagectomy are at risk of postoperative pulmonary complications. High-flow nasal cannula oxygen therapy delivers humidified, warmed positive airway pressure but has not been applied routinely after surgery. Here, we aimed to compare high-flow nasal cannula and conventional oxygen therapy in patients with esophageal cancer during intensive care unit hospitalization 48 h postoperatively.
In this prospective pre- and post-intervention study, patients with esophageal cancer who underwent elective minimally invasive esophagectomy (MIE) and were extubated in the operation room and admitted to the intensive care unit postoperatively were assigned to receive either high-flow nasal cannula (HFNCO) or standard oxygen (SO) therapy. Participants in the SO group were recruited before January 2020, and those in the HFNCO group were enrolled after January 2020. The primary outcome was the difference in postoperative pulmonary complication incidence. Secondary outcomes were the occurrence of desaturation within 48 h, PaO/FiO within 48 h, anastomotic leakage, length of intensive care unit and hospital stay, and mortality.
The standard oxygen and high-flow nasal cannula oxygen groups comprised 33 and 36 patients, respectively. Baseline characteristics were comparable between groups. In the HFNCO group, postoperative pulmonary complication incidence was significantly reduced (22.2% vs 45.5%) and PaO/FiO was significantly increased. No other between-group differences were observed.
HFNCO therapy significantly reduced postoperative pulmonary complication incidence after elective MIE in patients with esophageal cancer without increasing the risk of anastomotic leakage.
背景/目的:接受微创食管切除术的食管癌患者有术后肺部并发症的风险。高流量鼻导管给氧疗法可提供湿化、加温的气道正压,但术后尚未常规应用。在此,我们旨在比较食管癌患者术后48小时在重症监护病房住院期间高流量鼻导管给氧和传统氧疗的效果。
在这项前瞻性干预前后研究中,接受择期微创食管切除术(MIE)且在手术室拔管并于术后入住重症监护病房的食管癌患者被分配接受高流量鼻导管给氧(HFNCO)或标准氧疗(SO)。SO组的参与者在2020年1月之前招募,HFNCO组的参与者在2020年1月之后招募。主要结局是术后肺部并发症发生率的差异。次要结局包括48小时内的血氧饱和度下降情况、48小时内的PaO/FiO、吻合口漏、重症监护病房和住院时间以及死亡率。
标准氧疗组和高流量鼻导管给氧组分别有33例和36例患者。两组间基线特征具有可比性。在HFNCO组中,术后肺部并发症发生率显著降低(22.2%对45.5%),且PaO/FiO显著升高。未观察到其他组间差异。
HFNCO疗法显著降低了食管癌患者择期MIE术后的肺部并发症发生率,且未增加吻合口漏的风险。